AI assistant
AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2021
Feb 17, 2021
31580_dirs_2021-02-17_4cf715d7-aa3a-400b-a258-028c165deafa.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK: 0001439222
Period of Report: 2021-02-16
Reporting Person: Schenkein David P (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-02-16 | Common stock | M | 8125 | — | Acquired | 113178 | Direct |
| 2021-02-16 | Common stock | F | 2540 | — | Disposed | 110638 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-02-16 | Restricted stock units | $ | M | 8125 | Disposed | Common stock (8125.0) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common stock | 79082 | Indirect |
| Common stock | 270772 | Indirect |
Footnotes
F1: Shares held by Amy P. Schenkein 2004 Revocable Trust, of which the reporting person's spouse is trustee and beneficiary.
F2: Shares held by David P. Schenkein 2004 Revocable Trust, of which the reporting person is trustee and beneficiary.
F3: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F4: The restricted stock units were granted on February 16, 2018. Beginning on February 16, 2019, the shares underlying the restricted stock units will vest in three equal annual installments.